PMID- 19860642
OWN - NLM
STAT- MEDLINE
DCOM- 20100105
LR  - 20190911
IS  - 1873-5592 (Electronic)
IS  - 1389-4501 (Linking)
VI  - 10
IP  - 10
DP  - 2009 Oct
TI  - Targeting sarcomas: novel biological agents and future perspectives.
PG  - 937-49
AB  - Sarcomas are a group of heterogeneous tumors that arise from mesenchymal tissue 
      and account for approximately 1% of all adult solid malignancies diagnosed, 
      although its incidence approaches 20% in pediatric cancers. Characterization of 
      molecular abnormalities in patients with sarcomas, in particular the 
      up-regulation of the receptor tyrosine kinase and the PI3K-AKT-mTOR pathway, loss 
      or deletions of retinoblastoma (Rb) and p53 gene, increased VEGF expression and 
      angiogenesis, dysregulation of apoptosis through Bcl-2 overexpression, along with 
      oncogene mutations and activations, such as c-KIT in Gastrointestinal stromal 
      tumors (GISTs), makes treatment with novel biological therapies a promising 
      option. This review focuses on the molecular heterogeneity of soft tissue and 
      bone sarcomas, novel biological therapies currently in clinical trials to target 
      the various molecular pathways, and the potential biological agents in 
      pre-clinical and early clinical development.
FAU - Mahalingam, Devalingam
AU  - Mahalingam D
AD  - Institute for Drug Development, Cancer Therapy and Research Center at University 
      of Texas Health Science Center, 7979 Wurzbach Road, San Antonio, Texas 78229, 
      USA.
FAU - Mita, Alain
AU  - Mita A
FAU - Sankhala, Kamalesh
AU  - Sankhala K
FAU - Swords, Ronan
AU  - Swords R
FAU - Kelly, Kevin
AU  - Kelly K
FAU - Giles, Francis
AU  - Giles F
FAU - Mita, Monica M
AU  - Mita MM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Targets
JT  - Current drug targets
JID - 100960531
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biological Products)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Biological Products/pharmacology/therapeutic use
MH  - Bone Neoplasms/*drug therapy/genetics/physiopathology
MH  - Child
MH  - Clinical Trials as Topic
MH  - Drug Delivery Systems
MH  - Humans
MH  - Sarcoma/*drug therapy/genetics/physiopathology
MH  - Soft Tissue Neoplasms/*drug therapy/genetics/physiopathology
RF  - 131
EDAT- 2009/10/29 06:00
MHDA- 2010/01/06 06:00
CRDT- 2009/10/29 06:00
PHST- 2009/10/29 06:00 [entrez]
PHST- 2009/10/29 06:00 [pubmed]
PHST- 2010/01/06 06:00 [medline]
AID - 10.2174/138945009789577990 [doi]
PST - ppublish
SO  - Curr Drug Targets. 2009 Oct;10(10):937-49. doi: 10.2174/138945009789577990.